{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:03:50Z","timestamp":1791644630364,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["GSK 219912"],"award-info":[{"award-number":["GSK 219912"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03721-1","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:55:12Z","timestamp":1784526912000},"page":"4730-4748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Remission with FF\/UMEC\/VI Versus ICS\/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled Trial"],"prefix":"10.1007","volume":"43","author":[{"given":"Stephen G.","family":"Noorduyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amila","family":"Poddar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Slade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Baptist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Penz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"3721_CR1","unstructured":"Global Initiative for Asthma. 2026 Global Strategy for Asthma Management and Prevention. https:\/\/ginasthma.org\/2026-gina-strategy-report\/. Accessed Mar 2026."},{"key":"3721_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3109\/02770903.2013.846369","volume":"51","author":"D Price","year":"2014","unstructured":"Price D, Dale P, Elder E, et al. Types, frequency and impact of asthma triggers on patients\u2019 lives: a quantitative study in five European countries. J Asthma. 2014;51:127\u201335.","journal-title":"J Asthma"},{"key":"3721_CR3","doi-asserted-by":"publisher","first-page":"14009","DOI":"10.1038\/npjpcrm.2014.9","volume":"24","author":"D Price","year":"2014","unstructured":"Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.","journal-title":"NPJ Prim Care Respir Med"},{"key":"3721_CR4","doi-asserted-by":"publisher","first-page":"105859","DOI":"10.1016\/j.rmed.2019.105859","volume":"162","author":"R Buhl","year":"2020","unstructured":"Buhl R, Heaney LG, Loefroth E, et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting beta(2)-agonist in UK primary care settings. Respir Med. 2020;162:105859.","journal-title":"Respir Med"},{"key":"3721_CR5","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","volume":"8","author":"HAM Kerstjens","year":"2020","unstructured":"Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone\u2013indacaterol\u2013glycopyrronium versus mometasone\u2013indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase\u00a03 study. Lancet Respir Med. 2020;8:1000\u201312.","journal-title":"Lancet Respir Med"},{"key":"3721_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","volume":"9","author":"LA Lee","year":"2021","unstructured":"Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase\u00a03A trial. Lancet Respir Med. 2021;9:69\u201384.","journal-title":"Lancet Respir Med"},{"key":"3721_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2213-2600(25)00457-6","volume":"14","author":"A Papi","year":"2026","unstructured":"Papi A, Wise RA, Jackson DJ, et al. Budesonide\u2013glycopyrronium\u2013formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase\u00a03 trials. Lancet Respir Med. 2026;14:350\u201362.","journal-title":"Lancet Respir Med"},{"key":"3721_CR8","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","volume":"394","author":"JC Virchow","year":"2019","unstructured":"Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase\u00a03 trials. Lancet. 2019;394:1737\u201349.","journal-title":"Lancet"},{"key":"3721_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s41030-025-00288-0","volume":"11","author":"SG Noorduyn","year":"2025","unstructured":"Noorduyn SG, Begaj K, Martin A, et al. A brief report on a systematic review of real-world effectiveness studies of ICS\/LAMA\/LABA for treatment of adults with asthma in the US. Pulm Ther. 2025;11:159\u201376.","journal-title":"Pulm Ther"},{"key":"3721_CR10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s41030-025-00327-w","volume":"11","author":"AP Baptist","year":"2025","unstructured":"Baptist AP, Paczkowski R, Germain G, et al. Exacerbation reduction in patients with asthma following escalation to FF\/UMEC\/VI from ICS\/LABA: retrospective cohort study. Pulm Ther. 2025;11:725\u201340.","journal-title":"Pulm Ther"},{"key":"3721_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s41030-026-00346-1","volume":"12","author":"SG Noorduyn","year":"2026","unstructured":"Noorduyn SG, Brown N, Crawford J, et al. A pragmatic RCT of FF\/UMEC\/VI in patients with uncontrolled asthma: PERFORM protocol. Pulm Ther. 2026;12:397\u2013412.","journal-title":"Pulm Ther"},{"key":"3721_CR12","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.s599766","author":"ENS Penz","year":"2026","unstructured":"Penz ENS, Moore AC, Nagase H, et al. Effectiveness of FF\/UMEC\/VI versus ICS\/LABA in patients with uncontrolled asthma treated in routine clinical practice (PERFORM): a pragmatic randomized controlled trial. J Asthma Allergy. 2026. https:\/\/doi.org\/10.2147\/jaa.s599766.","journal-title":"J Asthma Allergy"},{"key":"3721_CR13","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","volume":"131","author":"M Blaiss","year":"2023","unstructured":"Blaiss M, Oppenheimer J, Corbett M, et al. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. 2023;131:782\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3721_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","volume":"145","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145:757\u201365.","journal-title":"J Allergy Clin Immunol"},{"key":"3721_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.resinv.2025.03.009","volume":"63","author":"J Tamaoki","year":"2025","unstructured":"Tamaoki J, Nagase H, Sano H, et al. Practical guidelines for asthma management (PGAM): digest edition. Respir Investig. 2025;63:405\u201321.","journal-title":"Respir Investig"},{"key":"3721_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.alit.2025.11.004","volume":"75","author":"H Nagase","year":"2026","unstructured":"Nagase H, Harada N, Tezuka J, et al. Consensus definition of clinical remission in asthma for the Japanese asthma prevention and management guidelines (JGL 2024): a modified Delphi survey and comprehensive review. Allergol Int. 2026;75:3\u201314.","journal-title":"Allergol Int"},{"key":"3721_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s12325-025-03442-x","volume":"43","author":"J Oppenheimer","year":"2025","unstructured":"Oppenheimer J, Pavord ID, Corbridge T, et al. Evaluating asthma clinical remission with inhaled therapy: post hoc analyses of CAPTAIN. Adv Ther. 2025;43:729\u201349.","journal-title":"Adv Ther"},{"key":"3721_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","volume":"99","author":"EF Juniper","year":"2005","unstructured":"Juniper EF, Svensson K, Mork AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99:553\u20138.","journal-title":"Respir Med"},{"key":"3721_CR19","doi-asserted-by":"publisher","first-page":"582286","DOI":"10.2147\/JAA.S582286","volume":"19","author":"C Gessner","year":"2026","unstructured":"Gessner C, Russell REK, Greulich T, et al. Real-world effectiveness and safety of single inhaler triple therapy with beclometasone\/ formoterol\/ glycopyrronium in moderate to severe asthma: TriMaximize study. J Asthma Allergy. 2026;19:582286.","journal-title":"J Asthma Allergy"},{"key":"3721_CR20","doi-asserted-by":"publisher","first-page":"100431","DOI":"10.1016\/j.jacig.2025.100431","volume":"4","author":"M Ishizuka","year":"2025","unstructured":"Ishizuka M, Sugimoto N, Kobayashi K, et al. Clinical remission of mild-to-moderate asthma: rates, contributing factors, and stability. J Allergy Clin Immunol Glob. 2025;4:100431.","journal-title":"J Allergy Clin Immunol Glob"},{"key":"3721_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jaip.2024.10.037","volume":"13","author":"K Oishi","year":"2025","unstructured":"Oishi K, Hamada K, Fukatsu-Chikumoto A, et al. Clinical remission in patients with biologic-na\u00efve asthma: a multicenter study in Japan. J Allergy Clin Immunol Pract. 2025;13:328\u201332.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3721_CR22","doi-asserted-by":"publisher","first-page":"101016","DOI":"10.1016\/j.waojou.2024.101016","volume":"18","author":"GW Canonica","year":"2025","unstructured":"Canonica GW, Blasi F, Paggiaro P, et al. Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: evidence from the Severe Asthma Network in Italy (SANI). World Allergy Organ J. 2025;18:101016.","journal-title":"World Allergy Organ J"},{"key":"3721_CR23","doi-asserted-by":"publisher","first-page":"AB235","DOI":"10.1016\/j.jaci.2024.12.722","volume":"155","author":"M Hanslot","year":"2025","unstructured":"Hanslot M, Brusselle G, Papi A, et al. Achieving asthma remission with extrafine beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP\/FF\/GB) pMDI in adults with moderate-to-severe asthma: a post-hoc analysis of the TRIMARAN and TRIGGER studies. J Allergy Clin Immunol. 2025;155:AB235.","journal-title":"J Allergy Clin Immunol"},{"key":"3721_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61101797","author":"A Tomasello","year":"2025","unstructured":"Tomasello A, Benfante A, Principe S, et al. Early initiation of biologic therapies to prevent severe asthma progression. Medicina (Kaunas). 2025. https:\/\/doi.org\/10.3390\/medicina61101797.","journal-title":"Medicina (Kaunas)"},{"key":"3721_CR25","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jaci.2025.05.033","volume":"156","author":"RK Katial","year":"2025","unstructured":"Katial RK, Wechsler ME, Akuthota P, et al. Consensus summary on the definition of asthma remission. J Allergy Clin Immunol. 2025;156:S20\u2013S24.","journal-title":"J Allergy Clin Immunol"},{"key":"3721_CR26","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.01333-2024","author":"A Mozaffaripour","year":"2025","unstructured":"Mozaffaripour A, Tcherner S, Durom E, et al. Airway mucus and (129)Xe MRI ventilation after single inhaler triple therapy in asthma. ERJ Open Res. 2025. https:\/\/doi.org\/10.1183\/23120541.01333-2024.","journal-title":"ERJ Open Res"},{"key":"3721_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12931-020-01398-w","volume":"21","author":"NC Day","year":"2020","unstructured":"Day NC, Kumar S, Criner G, et al. Single-inhaler triple therapy fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol and umeclidinium\/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respir Res. 2020;21:139.","journal-title":"Respir Res"},{"key":"3721_CR28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","volume":"196","author":"DA Lipson","year":"2017","unstructured":"Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196:438\u201346.","journal-title":"Am J Respir Crit Care Med"},{"key":"3721_CR29","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671\u201380.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03721-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03721-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03721-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:39:49Z","timestamp":1790609989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03721-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3721"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03721-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephen G Noorduyn, Alison C Moore, Jodie Crawford, Amila Poddar, Nicola Brown, and David Slade are employed by GSK and hold financial equities in GSK. Stephen G Noorduyn is a PhD candidate at McMaster University, Hamilton, ON, Canada. John J Oppenheimer has served on adjudication committees or data and safety monitoring boards for AstraZeneca, GSK, Novartis, and Sanofi-Regeneron; received consultancy fees from AstraZeneca, Amgen, Regeneron, ARS, Aquestive, GSK, and Sanofi; and received grants and personal fees from GSK. Hiroyuki Nagase has received speaker and consultation fees from AstraZeneca and GSK, and speaker fees from Kyorin Pharmaceutical, and Sanofi. Victoria Boon is an employee of GSK. Gabriel Garcia has participated in advisory boards for GSK, AstraZeneca, Sanofi, Novartis, and Boehringer Ingelheim; he has received honoraria for speaking at sponsored meetings from GSK, Boehringer Ingelheim, AstraZeneca, Sanofi, Phoenix, and Novartis; and is a principal investigator in trials sponsored by GSK, Boehringer Ingelheim, AstraZeneca, Novartis, Sanofi, PPD, Zambon, Parexel, Covance, IQVIA, and Chiesi. Alan P Baptist reports grant support from GSK, AstraZeneca, Genentech, and Teva. Erika Penz has grant funding from the Canadian Institute Health Research, Lung Saskatchewan, Saskatchewan Health Research Foundation, AstraZeneca, GSK, and Sanofi; has served as a consultant for AstraZeneca, GSK, Roche, Sanofi, and Saskatchewan Cancer Agency; has received speaker honoraria from AstraZeneca, Boehringer Ingelheim, Canadian Thoracic Society, Covis Pharma, GSK, Lung Saskatchewan, Sanofi-Genzyme, and Valeo Pharma; serves as the Past-President of the Canadian Thoracic Society and is a board member of the Canadian Institutes of Health Research- Institute for Cancer Research; has served as co-chair of the COPD Assembly for the Canadian Thoracic Society; and her institution has previously received equipment from AstraZeneca. She is Associate Editor of the COPD section of the\n                      CHEST\n                      Journal and has received honoraria and travel expenses from\n                      CHEST\n                      journal.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PERFORM was sponsored by GSK (219912\/NCT06372496) and conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Guideline for Good Clinical Practice, as well as applicable local regulations. Trial documents and protocol amendments received approval by relevant local institutional review boards and\/or independent ethics committees. All participants provided physically or digitally signed, informed consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}